NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

IGC Pharma, Inc. (IGC) Stock Analysis

IGC Pharma, Inc. (IGC) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

IGC

$0.24

−$0.00 (−1.02%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IGC with… →

IGC Key Statistics

As of Oct 21, 2026
Trading
Open
$0.25
Previous Close
$0.25
Day's Range
0.24–0.25
52-Week Range
0.24–0.45
Volume
363.31K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.48
Valuation
Market Cap
$25.07M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
22.67
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.07
Financials (FY)
Revenue (FY)
$1.27M−5.50%
Net Income (FY)
−$7.12M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.38M
1-Year Return
−37.82%
Dividend and dates
Avg Volume
726.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IGC closed at $0.24, −37.82% over 1 year.

IGC Pharma, Inc. (IGC) has a market capitalization of $25.07M.

In fiscal 2024, IGC reported revenue of $1.27M.

IGC Stock Return by Calendar Year

IGC Pharma, Inc. (IGC) 10-year return: what $10,000 became

1 year
$10,000 $6,218
−37.82%
5 years
$10,000 $1,650
−83.50%
10 years
$10,000 $5,511
−44.89%

If you had invested $10,000 in IGC Pharma, Inc. (IGC) 10 years ago, at the close on October 21, 2016, it would have been worth $5,511 at the close on October 21, 2026: −44.89% in total, −5.78% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−13.39%
2025−17.65%
2024+21.43%
2023−12.50%
2022−67.35%
2021−37.18%
2020+147.62%
2019+125.00%
2018−72.00%
2017+257.14%
2016 (partial year)−47.17%

As of October 21, 2026.

IGC Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2024$1.27M−$7.12M−560.3%
2023$1.35M−$13.00M−966.5%
2022$911.00K−$11.51M−1,263.0%
2021$397.00K−$15.02M−3,782.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$1.27M$619.00K−$7.45M−$7.12M−560.3%
2023$1.35M$733.00K−$9.80M−$13.00M−966.5%
2022$911.00K$442.00K−$11.57M−$11.51M−1,263.0%
2021$397.00K$194.00K−$15.43M−$15.02M−3,782.4%

Annual figures as reported, in the company's reporting currency. As of March 31, 2025.

IGC Valuation vs Biotechnology Median

Median of 608 stocks
MetricIGCBiotechnology medianvs median
P/S ratio22.6713.3070% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IGC Pharma, Inc. (IGC) is capitalised at $25.07M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 70 employees.

The 52-week range on file runs from $0.24 to $0.45. The most recent close on file for IGC is $0.24, dated October 21, 2026. That is $0.00 (−1.02%) against the previous close. The latest close sits 1.04% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $1.27M. Against the prior fiscal year total of $1.35M, that is a change of −5.50%. The same year closed with a net loss of $7.12M. Earnings per share on a trailing basis come to −0.07.

Across the 4 fiscal years on file, revenue moves from $397.00K in 2021 to $1.27M in 2024. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 22.67. On price-to-sales that is 70.45% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −37.82%. Across 10 years the annualized return works out at −5.78%. Beta against the wider market is reported at 0.48. Annualized volatility over the trailing 10 years is 209.01%.

Growth & Income

No dividend is on file for IGC.

So far in 2026 the total return is −13.39%. The strongest complete calendar year on file is 2017 at +257.14%; the weakest is 2018 at −72.00%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

IGC Pharma, Inc. (IGC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IGC Pharma, Inc. IGC $25.07M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. IGC Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Visit website →